Targeting TAK1 to overcome cisplatin resistance in lung adenocarcinoma by rewiring the NF-κB and p53 signaling
Biochemical Pharmacology · 2026-10 · 252 · 118206
DOI: 10.1016/j.bcp.2026.118206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-10. Verfasst von Wenyan Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases…. Hauptthemen laut MEDLINE: Cisplatin, MAP Kinase Kinase Kinases, Drug Resistance, Neoplasm, Tumor Suppressor Protein p53. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hainan Provincial Department of Science and Technology.
Abstract (Originalsprache)
Acquired cisplatin resistance limits the efficacy of chemotherapy in advanced non-small cell lung cancer (NSCLC). Identifying key resistance regulators is clinically important. Although TAK1 (transforming growth factor-beta-activated kinase 1) has been implicated in drug resistance, its role in cisplatin-resistant lung adenocarcinoma remains unclear. Bioinformatic analysis of Gene Expression Omnibus (GEO) data identified TAK1 as a resistance-related gene. TAK1 expression was elevated in resistant clinical samples and cell lines (A549R, PC9R), positively correlating with the upregulation of drug-efflux proteins P-glycoprotein (P-gp) and ATP-binding cassette subfamily G member 2 (ABCG2). The TAK1 inhibitor (5Z)-7-oxozeaenol (5Z7) synergized with cisplatin to suppress proliferation and epithelial-mesenchymal transition, induce apoptosis, cause G0/G1 arrest, and promote senescence in resistant cells. Genetic TAK1 inhibition produced similar trends. Mechanistically, 5Z7 inhibited the TAK1-IκB kinase (IKK) axis, blocking inhibitor of κBα (IκBα) phosphorylation and nuclear factor kappa-B (NF-κB) p65 nuclear translocation, while upregulating p53 and its downstream effectors p21/p16-effects that were reversible by an NF-κB activator or p53 inhibitor. In vivo, 5Z7 plus cisplatin suppressed resistant tumor growth without notable organ toxicity. This study establishes TAK1 as a key hub in cisplatin resistance and shows that 5Z7 reverses resistance by targeting TAK1 to coordinately regulate NF-κB/p53 signaling, providing a foundation for potential clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases, The Hainan Branch of National Clinical Research Center for Cancer, T…
- Department of Pathology, Hainan Women and Children Medical Center, Hainan Medical University, Haikou 570312.
- Department of Pathophysiology, School of Basic Medicine Sciences, Guangdong Medical University, 524023 Zhanjiang, China. Electronic address: shenzh@gdmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Hainan Provincial Department of Science and Technology
Zitieren
APA
Lu, W., Tang, K., Wang, Z., Li, J., Shi, K., Wan, Z., Shen, Z., Jie, W., & Zheng, S. (2026). Targeting TAK1 to overcome cisplatin resistance in lung adenocarcinoma by rewiring the NF-κB and p53 signaling. Biochemical Pharmacology, 252, 118206. https://doi.org/10.1016/j.bcp.2026.118206
Vancouver
Lu W, Tang K, Wang Z, Li J, Shi K, Wan Z, et al. Targeting TAK1 to overcome cisplatin resistance in lung adenocarcinoma by rewiring the NF-κB and p53 signaling. Biochemical Pharmacology. 2026;252:118206. doi:10.1016/j.bcp.2026.118206
BibTeX
@article{Lu2026,
author = {Lu, Wenyan and Tang, Kunhao and Wang, Zechen and Li, Jiaqi and Shi, Kaijia and Wan, Zhenling and Shen, Zhihua and Jie, Wei and Zheng, Shaojiang},
title = {Targeting TAK1 to overcome cisplatin resistance in lung adenocarcinoma by rewiring the NF-κB and p53 signaling},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {252},
pages = {118206},
doi = {10.1016/j.bcp.2026.118206}
}
EUVIMED